Biotech takes a hit as dealmakers take a knee in Q3
A chill wind blew through the biopharma industry in the third quarter as the pace of M&A from the first half of the year cooled down, big upfront licensing deals slackened and venture investing slowed ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.